secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001420720-25-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio Q2 FY2025 net loss $4.4M; cash $7.2M; advances pipeline
------------------------------------------------------------

- Revenue $0.2M; net loss $4.4M ($0.48/shr) vs $4.5M ($2.42/shr) prior year.
- Cash & equivalents $7.2M as of Dec 31, 2024, including $0.2M restricted.
- Discovered novel Activin E antibody; in-licensed anti-myostatin IBIO-600 in Jan 2025.
- Initiated bispecific myostatin/activin A program; plans clinical investigation in 2026.
- Board added David Arkowitz and António Parada; insider private placement closed Jan 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000010/0001420720-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000010/ibio-20250210x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer